| Abatacept for treating active idiopathic inflammatory myopathies [TSID10095] | Technology appraisal guidance |
| Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389] | Technology appraisal guidance |
| Acalabrutinib with R-CHOP for untreated non-germinal centre B-cell diffuse large B-cell lymphoma [ID6614] | Technology appraisal guidance |
| Acalabrutinib with venetoclax and obinutuzumab for untreated chronic lymphocytic leukaemia [ID6156] | Technology appraisal guidance |
| Adagrasib with cetuximab for treating KRAS G12C mutation-positive advanced colorectal cancer after 1 treatment line [ID6694] | Technology appraisal guidance |
| Adalimumab for treating early Dupuytren's contracture [ID6276] | Technology appraisal guidance |
| Afamitresgene autoleucel for previously treated MAGE-A4 positive advanced synovial sarcoma or myxoid round cell liposarcoma [ID4064] | Technology appraisal guidance |
| Aficamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6668] | Technology appraisal guidance |
| AI technologies to aid the scoring and interpretation of diagnostic sleep studies | HealthTech guidance |
| AK-OTOF for treating hearing loss caused by otoferlin gene variants [ID6735] | Technology appraisal guidance |
| Allo-APZ2-CVU for treating chronic venous leg ulcers [ID6754] | Technology appraisal guidance |
| Allo-APZ2-EB for treating dystrophic and junctional epidermolysis bullosa in people of any age [ID6746] | Technology appraisal guidance |
| Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252] | Technology appraisal guidance |
| Alpha-1 antitrypsin for treating high-risk acute graft-versus-host disease after a haematopoietic stem cell transplant in people 12 years and over [ID6664] | Technology appraisal guidance |
| Apalutamide with gonadotrophin-releasing hormone agonist and radiotherapy for treating high-risk, localised or locally advanced prostate cancer [ID6215] | Technology appraisal guidance |
| Apalutamide with radical prostatectomy for untreated high-risk, localised or locally advanced prostate cancer [ID6471] | Technology appraisal guidance |
| Apraglutide for treating short bowel syndrome
[ID6533] | Technology appraisal guidance |
| Aprocitentan for treating resistant hypertension [ID6681] | Technology appraisal guidance |
| Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment | HealthTech guidance |
| Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care | HealthTech guidance |
| Artificial intelligence (AI)-derived software to help clinical decision making in stroke | HealthTech guidance |
| Atezolizumab with chemotherapy for adjuvant treatment of stage 3 colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID6646] | Technology appraisal guidance |
| Atrasentan for treating primary IgA nephropathy [ID6558] | Technology appraisal guidance |
| Avexitide for treating hypoglycaemia after bariatric surgery [ID6725] | Technology appraisal guidance |
| Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794] | Technology appraisal guidance |
| Baricitinib for treating severe or very severe alopecia areata in people 6 to 17 years [ID6541] | Technology appraisal guidance |
| Belzutifan for treating advanced pheochromocytoma or paraganglioma [ID6719] | Technology appraisal guidance |
| Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476] | Technology appraisal guidance |
| Belzutifan with pembrolizumab and lenvatinib for untreated advanced clear cell renal cell carcinoma [ID6605] | Technology appraisal guidance |
| Belzutifan with pembrolizumab for adjuvant treatment of clear cell renal cell carcinoma after nephrectomy [ID6645] | Technology appraisal guidance |
| Benegrastim for treating chemotherapy-induced neutropenia in people with breast cancer [TSID11769] | Technology appraisal guidance |
| Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322] | Technology appraisal guidance |
| Bentracimab for reversing the antiplatelet activity of ticagrelor [ID6344] | Technology appraisal guidance |
| Bictegravir–lenacapavir for treating HIV-1 [ID6744] | Technology appraisal guidance |
| Bifikafusp alfa–onfekafusp alfa for neoadjuvant treatment of 3B or 3C resectable melanoma [ID6384] | Technology appraisal guidance |
| Bimekizumab for treating ankylosing spondylitis [ID4011] | Technology appraisal guidance |
| Blarcamesine for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6679] | Technology appraisal guidance |
| Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286] | Technology appraisal guidance |
| Budesonide (Jorveza) for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486] | Technology appraisal guidance |
| Bupivacaine–meloxicam for treating postoperative pain [ID2728] | Technology appraisal guidance |
| Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731] | Technology appraisal guidance |
| Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387] | Technology appraisal guidance |
| CAEL-101 with standard care for untreated amyloid light chain amyloidosis [ID6210] | Technology appraisal guidance |
| Camizestrant as an add-on to palbociclib and abemaciclib for untreated hormone receptor-positive HER2-negative metastatic breast cancer with an ESR1 mutation
[ID6535] | Technology appraisal guidance |
| Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348] | Technology appraisal guidance |
| Camizestrant for treating oestrogen receptor-positive HER2-negative early breast cancer at risk of recurrence after 2 to 5 years of adjuvant endocrine treatment [TSID12348] | Technology appraisal guidance |
| Camizestrant with palbociclib for untreated oestrogen receptor-positive HER2-negative metastatic breast cancer after adjuvant endocrine treatment [ID6534] | Technology appraisal guidance |
| Camlipixant for treating refractory or unexplained chronic cough [ID6722] | Technology appraisal guidance |
| Capivasertib with abiraterone for treating hormone-sensitive metastatic prostate cancer with PTEN deficiency [ID6466] | Technology appraisal guidance |
| Carfilzomib in combination for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID12176] | Technology appraisal guidance |
| Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214] | Technology appraisal guidance |
| CM-AT for behaviours associated with autism in children and young people [ID6731] | Technology appraisal guidance |
| Concizumab for treating severe haemophilia A or moderate to severe haemophilia B in people 12 years and over without inhibitors [ID5099] | Technology appraisal guidance |
| Cosibelimab for treating advanced cutaneous squamous cell carcinoma [ID6663] | Technology appraisal guidance |
| Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source [ID1417] | Technology appraisal guidance |
| Dabrafenib, trametinib or both for treating BRAF V600 mutation-positive unresectable or metastatic melanoma in people aged 12 and over [TSID11838] | Technology appraisal guidance |
| Daratumumab for treating high-risk smouldering multiple myeloma [ID6214] | Technology appraisal guidance |
| Datopotamab deruxtecan for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer [ID6435] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab and carboplatin for untreated TROP2-positive advanced non-small-cell lung cancer without actionable genomic alterations [ID6522] | Technology appraisal guidance |
| Datopotamab deruxtecan with durvalumab for treating triple-negative breast cancer when there is residual invasive disease after neoadjuvant systemic treatment and surgery [ID6643] | Technology appraisal guidance |
| DB-OTO for Hearing loss [ID6728] | Technology appraisal guidance |
| Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897] | Technology appraisal guidance |
| Delgocitinib for Chronic Hand Eczema [ID6688] | Technology appraisal guidance |
| Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150] | Technology appraisal guidance |
| Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160] | Technology appraisal guidance |
| Deucravacitinib for treating active psoriatic arthritis [ID6561] | Technology appraisal guidance |
| Deucravacitinib for treating active Sjogren's syndrome [ID6715] | Technology appraisal guidance |
| Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154] | Technology appraisal guidance |
| Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675] | Technology appraisal guidance |
| Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521] | Technology appraisal guidance |
| Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660] | Technology appraisal guidance |
| Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [ID6747] | Technology appraisal guidance |
| Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484] | Technology appraisal guidance |
| Dulaglutide for treating type 2 diabetes [ID1451] | Technology appraisal guidance |
| Dupilumab for treating bullous pemphigoid [ID6479] | Technology appraisal guidance |
| Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492] | Technology appraisal guidance |
| Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736] | Technology appraisal guidance |
| Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206] | Technology appraisal guidance |
| Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254] | Technology appraisal guidance |
| Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080] | Technology appraisal guidance |
| Durvalumab with bevacizumab and transarterial chemoembolisation for treating locally advanced hepatocellular carcinoma [ID3944] | Technology appraisal guidance |
| Durvalumab with bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6146] | Technology appraisal guidance |
| Durvalumab with chemoradiation for untreated unresectable locally advanced oesophageal squamous cell cancer
[ID6490] | Technology appraisal guidance |
| Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445] | Technology appraisal guidance |
| Durvalumab with oleclumab or monalizumab for treating unresectable locally advanced non-small-cell lung cancer after platinum-based chemoradiotherapy [ID6626] | Technology appraisal guidance |
| Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428] | Technology appraisal guidance |
| Durvalumab with radiotherapy for treating unresected node-negative stage 1 or 2 non-small-cell lung cancer [ID6567] | Technology appraisal guidance |
| Durvalumab with transarterial chemoembolisation for treating incurable locally advanced hepatocellular carcinoma [ID5124] | Technology appraisal guidance |
| Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855] | Technology appraisal guidance |
| Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma PD [ID6527] | Technology appraisal guidance |
| Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830] | Technology appraisal guidance |
| Edaravone for treating amyotrophic lateral sclerosis [TSID11869] | Technology appraisal guidance |
| Eflornithine with lomustine for treating anaplastic astrocytoma after radiotherapy and adjuvant temozolomide [TSID10046] | Technology appraisal guidance |
| Efzimfotase alfa for treating hypophosphatasia [ID6633] | Technology appraisal guidance |
| Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753] | Technology appraisal guidance |
| Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359] | Technology appraisal guidance |
| Elinzanetant for Vasomotor symptoms [ID6544] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after 2 treatments [ID6464] | Technology appraisal guidance |
| Elranatamab for treating relapsed or refractory multiple myeloma after treatments including anti-CD38 antibody and lenalidomide therapy [ID6591] | Technology appraisal guidance |
| Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734] | Technology appraisal guidance |
| Endouterine-ultrasound guided transcervical radiofrequency ablation for fibroids | HealthTech guidance |
| Eneboparatide for treating chronic hypoparathyroidism [ID6532] | Technology appraisal guidance |
| Eneboparatide for treating chronic hypoparathyroidism [TSID12145] | Technology appraisal guidance |
| Enlicitide decanoate for treating hyperlipidaemia in people at risk of an atherosclerotic cardiovascular disease event [ID6656] | Technology appraisal guidance |
| Ensitrelvir for treating COVID 19 [ID6231] | Technology appraisal guidance |
| Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment [ID6463] | Technology appraisal guidance |
| Epcoritamab with R-CHOP for newly diagnosed diffuse large B-cell lymphoma [ID6701] | Technology appraisal guidance |
| Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy [TSID12015] | Technology appraisal guidance |
| Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 [ID4037] | Technology appraisal guidance |
| Etavopivat for treating sickle cell disease in people 12 years and over [ID6698] | Technology appraisal guidance |
| Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827] | Technology appraisal guidance |
| Excimer Laser Trabeculotomy (ELT) for glaucoma | HealthTech guidance |
| Fenebrutinib for treating primary progressive multiple sclerosis [ID6543] | Technology appraisal guidance |
| Fenebrutinib for treating relapsing multiple sclerosis [ID6577] | Technology appraisal guidance |
| Fenfluramine for treating seizures caused by CDKL5 deficiency disorder in people 1 year and over [ID6740] | Technology appraisal guidance |
| Fianlimab with cemiplimab for untreated unresectable advanced melanoma or adjuvant treatment of completely resected high-risk melanoma [ID6721] | Technology appraisal guidance |
| Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726] | Technology appraisal guidance |
| Gantenerumab for treating early Alzheimer's disease [TSID10668] | Technology appraisal guidance |
| Gemcitabine intravesical delivery system for treating high-risk non-muscle-invasive bladder cancer untreated with BCG [ID6658] | Technology appraisal guidance |
| Gemcitabine intravesical delivery system for treating recurrent high-risk papillary non-muscle-invasive bladder after BCG [ID6657] | Technology appraisal guidance |
| Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies | HealthTech guidance |
| Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [ID6704] | Technology appraisal guidance |
| Gilteritinib with standard chemotherapy for newly diagnosed FLT3-mutation-positive acute myeloid leukaemia when intensive chemotherapy is suitable [TSID12331] | Technology appraisal guidance |
| Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576] | Technology appraisal guidance |
| Giredestrant with palbociclib for untreated oestrogen-receptor positive HER2-negative advanced breast cancer [ID5072] | Technology appraisal guidance |
| Golimumab biosimilar for Rheumatoid Arthritis, Juvenile Arthritis, Ankylosing Spondylitis, Axial Spondyloarthropathy, Psoriatic Arthritis, and Ulcerative Colitis [ID12208] | Technology appraisal guidance |
| Gosuranemab for treating progressive supranuclear palsy [ID1607] | Technology appraisal guidance |
| Hepatocellular carcinoma (unresectable, untreated) - tislelizumab [ID6129] | Technology appraisal guidance |
| Human acellular vessel (Humacyl; HAV) For use as an arterial venous access for patients with end stage renal disease (ESRD) requiring haemodialysis [ID3747] | Technology appraisal guidance |
| Ianalumab for treating active Sjogren's syndrome [ID6634] | Technology appraisal guidance |
| Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720] | Technology appraisal guidance |
| ID6611 Obesity, overweight - semaglutide (including review of TA875) | Technology appraisal guidance |
| Imetelstat for treating intermediate-2 or high-risk relapsed or refractory myelofibrosis after a JAK inhibitor [TSID8376] | Technology appraisal guidance |
| Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650] | Technology appraisal guidance |
| Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129] | Technology appraisal guidance |
| Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430] | Technology appraisal guidance |
| Inebilizumab for treating generalised myasthenia gravis [ID6587]
[TSID12110] | Technology appraisal guidance |
| Inebilizumab for treating immunoglobulin G4-related disease
[TSID12107] | Technology appraisal guidance |
| Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923] | Technology appraisal guidance |
| Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190] | Technology appraisal guidance |
| Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355] | Technology appraisal guidance |
| Iptacopan for treating primary IgA nephropathy
[ID6640] | Technology appraisal guidance |
| Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469] | Technology appraisal guidance |
| Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable [TSID11949] | Technology appraisal guidance |
| Isatuximab in combination for maintenance treatment of newly diagnosed multiple myeloma after an autologous stem cell transplant [ID6639] | Technology appraisal guidance |
| Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868] | Technology appraisal guidance |
| Itepekimab as add-on maintenance treatment for moderate to severe chronic obstructive pulmonary disease [ID6547] | Technology appraisal guidance |
| Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745] | Technology appraisal guidance |
| Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590] | Technology appraisal guidance |
| KardiaMobile 6L for measuring cardiac QT interval in adults having antipsychotic medication | HealthTech guidance |
| LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022] | Technology appraisal guidance |
| Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor [ID6305] | Technology appraisal guidance |
| Leriglitazone for treating X-linked andrenoleukodystrophy [TSID9996] | Technology appraisal guidance |
| Letetresgene autoleucel for treating NY-ESO-1 advanced unresectable synovial sarcoma in people aged 10 and over or NY-ESO-1 advanced unresectable myxoid round cell liposarcoma in adults [TSID10652] | Technology appraisal guidance |
| Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727] | Technology appraisal guidance |
| Linerixibat for treating pruritus in people with primary biliary cholangitis [ID6265] | Technology appraisal guidance |
| Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory low-grade B-cell follicular lymphoma after 1 or more treatments [ID6564] | Technology appraisal guidance |
| Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695] | Technology appraisal guidance |
| Loncastuximab Tesirine + Rituximab for Diffuse large B-cell lymphoma [ID6686] | Technology appraisal guidance |
| Luspatercept for treating anaemia caused by myelodysplastic syndromes (including review of TA844) [ID6696] | Technology appraisal guidance |
| Luspatercept for treating anaemia caused by myelofibrosis [ID6697] | Technology appraisal guidance |
| Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870] | Technology appraisal guidance |
| Luspatercept for treating haemoglobin H disease [ID6714] | Technology appraisal guidance |
| Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after an anti-androgen but not a taxane [ID6743] | Technology appraisal guidance |
| Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy
[TSID12143] | Technology appraisal guidance |
| Mavorixafor for treating WHIM syndrome [ID3946] | Technology appraisal guidance |
| Medicines for treating osteoporosis and reducing the risk of fragility fractures (review of TA160, TA161, TA204, TA464, TA791, TA991) [ID6689] | Technology appraisal guidance |
| Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate
[ID6677] | Technology appraisal guidance |
| Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513] | Technology appraisal guidance |
| Miniature lens system implantation for advanced age-related macular degeneration | HealthTech guidance |
| Mosunetuzumab with lenalidomide for treating relapsed or refractory follicular lymphoma after 1 or more systemic treatments [ID6655] | Technology appraisal guidance |
| Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538] | Technology appraisal guidance |
| Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769] | Technology appraisal guidance |
| Nedosiran treating primary hyperoxaluria type 1 in people 6 years and over [TSID11777] | Technology appraisal guidance |
| Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078] | Technology appraisal guidance |
| Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain | HealthTech guidance |
| Nicardipine (Nicaplant) for aneurysmal subarachnoid haemorrhage patients undergoing aneurysm clipping [TSID10593] | Technology appraisal guidance |
| Nipocalimab for treating generalised myasthenia gravis [ID6562] | Technology appraisal guidance |
| Nipocalimab for treating warm autoimmune haemolytic anaemia [ID6642] | Technology appraisal guidance |
| Niraparib with abiraterone acetate and prednisone for treating hormone-sensitive metastatic prostate cancer [ID6595] | Technology appraisal guidance |
| Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321] | Technology appraisal guidance |
| Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma [TSID9659] | Technology appraisal guidance |
| Obinutuzumab for treating childhood-onset idiopathic nephrotic syndrome in people 2 years and over [ID6692] | Technology appraisal guidance |
| Obinutuzumab for treating primary membranous nephropathy [ID6751] | Technology appraisal guidance |
| OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687] | Technology appraisal guidance |
| Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627] | Technology appraisal guidance |
| Odronextamab for treating relapsed or refractory follicular lymphoma [ID6726] | Technology appraisal guidance |
| Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912] | Technology appraisal guidance |
| Ondansetron for treating alcohol-use disorder [ID6341] | Technology appraisal guidance |
| Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323] | Technology appraisal guidance |
| Ovarian, fallopian tube, peritoneal cancer (platinum sensitive) - rucaparib (with nivolumab, maintenance, after 1 therapy) [ID6128] | Technology appraisal guidance |
| Oveporexton for treating type 1 narcolepsy [ID6622] | Technology appraisal guidance |
| Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846] | Technology appraisal guidance |
| Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865] | Technology appraisal guidance |
| Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural
mesothelioma [ID1575] | Technology appraisal guidance |
| Pelacarsen for reducing the risk of cardiovascular events in people with established cardiovascular disease and high lipoprotein (a) [ID6559] | Technology appraisal guidance |
| Pembrolizumab for adjuvant treatment of triple-negative breast cancer after neoadjuvant chemotherapy [ID6546] | Technology appraisal guidance |
| Pembrolizumab for treating advanced or recurrent endometrial cancer with mismatch repair deficiency [ID6710] | Technology appraisal guidance |
| Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk advanced cervical cancer [TSID10690] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer [ID6613] | Technology appraisal guidance |
| Pembrolizumab with chemoradiation, then with or without olaparib, for untreated unresectable locally advanced non-small-cell lung cancer [ID6399] | Technology appraisal guidance |
| Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [TSID11808] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219] | Technology appraisal guidance |
| Pembrolizumab with chemotherapy for treating hormone receptor-positive HER2-negative locally recurrent inoperable or metastatic breast cancer [ID6285] | Technology appraisal guidance |
| Pembrolizumab with enzalutamide and androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer [TSID11810] | Technology appraisal guidance |
| Pembrolizumab with neoadjuvant chemotherapy and adjuvant endocrine therapy for treating ER-positive, HER2-negative early breast cancer [ID3993] | Technology appraisal guidance |
| Pembrolizumab with olaparib and chemoradiation for
previously untreated limited-stage small-cell lung cancer [ID6412] | Technology appraisal guidance |
| Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587] | Technology appraisal guidance |
| Percutaneous insertion of a temporary heart pump for left ventricular haemodynamic support in high-risk percutaneous coronary interventions | HealthTech guidance |
| Percutaneous transluminal renal sympathetic denervation for resistant hypertension | HealthTech guidance |
| Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma untreated with a BTK inhibitor [ID6493] | Technology appraisal guidance |
| Pirtobrutinib with venetoclax and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6566] | Technology appraisal guidance |
| Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895] | Technology appraisal guidance |
| PLX-PAD for treating muscle injury after arthroplasty for hip fracture in people 60 to 90 years [ID3989] | Technology appraisal guidance |
| Point-of-care lipid tests for cardiovascular disease prevention in primary and community care | HealthTech guidance |
| Port Delivery Platform with ranibizumab for treating wet age-related macular degeneration [ID3983] | Technology appraisal guidance |
| Pozelimab with cemdisiran for treating symptomatic generalised myasthenia gravis [ID6720] | Technology appraisal guidance |
| Pridopidine for treating Huntington's disease [ID6525] | Technology appraisal guidance |
| ProKnow cloud-based system for radiotherapy data storage, communication and management | HealthTech guidance |
| Prostate cancer (hormone relapsed, homologous recombination deficiency, metastatic) – rucaparib (after 1 therapy) [ID6127] | Technology appraisal guidance |
| PXT3003 for treating Charcot-Marie-Tooth disease type 1A in people aged 16 and over [ID1439] | Technology appraisal guidance |
| Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases [ID6512] | Technology appraisal guidance |
| Ranibizumab port delivery system for treating diabetic macular oedema [ID6137] | Technology appraisal guidance |
| Ravulizumab for preventing kidney events in people with chronic kidney disease at high risk after a cardiopulmonary bypass [ID6632] | Technology appraisal guidance |
| Ravulizumab for treating primary IgA nephropathy [ID6703] | Technology appraisal guidance |
| Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642][ID6319] | Technology appraisal guidance |
| Remdesivir for treating COVID 19 [ID3808] | Technology appraisal guidance |
| Remibrutinib for treating chronic inducible urticaria inadequately controlled by H1-antihistamines [ID6742] | Technology appraisal guidance |
| Remibrutinib for treating chronic spontaneous urticaria inadequately controlled by H1-antihistamines in people 12 to 17 years [ID6649] | Technology appraisal guidance |
| Retatrutide for managing overweight and obesity
[ID6644] | Technology appraisal guidance |
| Retifanlimab with chemotherapy for previously untreated metastatic non-small-cell lung cancer [ID6436] | Technology appraisal guidance |
| Riliprubart for treating chronic inflammatory demyelinating polyneuropathy [TSID12314] | Technology appraisal guidance |
| Ritlecitinib for treating non-segmental vitiligo in people 12 years and over [ID6584] | Technology appraisal guidance |
| Rivaroxaban for treating chronic heart failure [ID1462] | Technology appraisal guidance |
| Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819] | Technology appraisal guidance |
| Rucaparib for treating hormone-relapsed metastatic prostate cancer with homologous recombination deficiency after 1 therapy [TSID10764] | Technology appraisal guidance |
| Rucaparib with nivolumab for maintenance treatment of platinum-sensitive advanced ovarian, fallopian tube or peritoneal cancer after 1 therapy [TSID10763] | Technology appraisal guidance |
| Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709] | Technology appraisal guidance |
| Ruxolitinib for Prurigo Nodularis [ID6571] | Technology appraisal guidance |
| Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410] | Technology appraisal guidance |
| Ruxolitinib for treating moderate atopic dermatitis [ID6602] | Technology appraisal guidance |
| Sabizabulin for treating COVID 19 [TSID11814] | Technology appraisal guidance |
| Sacituzumab govitecan for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6592] | Technology appraisal guidance |
| Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer [ID6433] | Technology appraisal guidance |
| Sacituzumab tirumotecan for treating advanced or metastatic gastric, gastro-oesophageal junction or oesophageal adenocarcinoma after 2 or more treatment lines [ID6723] | Technology appraisal guidance |
| Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506] | Technology appraisal guidance |
| Satralizumab for treating thyroid eye disease [ID6648] | Technology appraisal guidance |
| Savolitinib with durvalumab for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID6520] | Technology appraisal guidance |
| Savolitinib with osimertinib for treating EGFR-mutated MET-overexpressed or amplified advanced non-small-cell lung cancer after osimertinib
[ID6494] | Technology appraisal guidance |
| Secukinumab for treating relapsed polymyalgia rheumatica [ID6599] | Technology appraisal guidance |
| Selinexor with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 to 4 treatment lines in people who have not had pomalidomide [ID6705] | Technology appraisal guidance |
| Selinexor with ruxolitinib for treating splenomegaly or symptoms in myelofibrosis untreated with a JAK inhibitor [ID6717] | Technology appraisal guidance |
| Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699] | Technology appraisal guidance |
| Semaglutide for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease
[ID6635] | Technology appraisal guidance |
| Semaglutide for treating type 2 diabetes [ID1450] | Technology appraisal guidance |
| Sepiapterin for treating hyperphenylalaninaemia in phenylketonuria in people of any age [ID6750] | Technology appraisal guidance |
| Serplulimab with chemotherapy for neoadjuvant and adjuvant treatment of untreated gastric cancer [TSID12350] | Technology appraisal guidance |
| Setrusumab for treating osteogenesis imperfecta [ID6730] | Technology appraisal guidance |
| Sevabertinib for untreated HER2-positive advanced non-small-cell lung cancer [ID6616] | Technology appraisal guidance |
| Sibeprenlimab for treating IgA nephropathy [ID6604] | Technology appraisal guidance |
| Sigvotatug vedotin for Non-small-cell lung cancer [ID6718] | Technology appraisal guidance |
| Somapacitan for treating growth failure associated with being small for gestational age, Noonan syndrome or idiopathic short height [ID6536] | Technology appraisal guidance |
| Somapacitan for treating growth failure caused by Turner syndrome in people 2 to 17 years [ID6621] | Technology appraisal guidance |
| Sonesitatug vedotin for previously treated metastatic claudin 18.2-positive gastric or gastro-oesophageal junction adenocarcinomar [ID6669] | Technology appraisal guidance |
| Sotagliflozin for treating type 2 diabetes [ID1657] | Technology appraisal guidance |
| Sotorasib with pemetrexed and carboplatin for untreated KRAS G12C mutation-positive advanced non-small-cell lung cancer [ID6741] | Technology appraisal guidance |
| Sparsentan for treating focal segmental glomerulosclerosis in people 8 years and over [ID3955] | Technology appraisal guidance |
| STG320 for treating allergic rhinitis or rhinoconjunctivitis caused by house dust mites [ID1278] | Technology appraisal guidance |
| Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977] | Technology appraisal guidance |
| Subcutaneous mosunetuzumab for treating relapsed or refractory follicular lymphoma after 2 or more treatments TSID 12081 | Technology appraisal guidance |
| Sugemalimab for consolidation treatment of locally advanced or unresectable non-small-cell lung cancer after chemoradiotherapy [ID6737] | Technology appraisal guidance |
| Surovatamig for treating relapsed or refractory B-cell acute lymphoblastic leukaemia after 2 or more lines of treatment in people 12 years and over [ID6630] | Technology appraisal guidance |
| Surovatamig for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more lines of treatment
[ID6631] | Technology appraisal guidance |
| Surovatamig for treating relapsed or refractory follicular lymphoma after 2 or more treatment lines [TSID12354] | Technology appraisal guidance |
| Survodutide for managing overweight and obesity [ID6752] | Technology appraisal guidance |
| Sutimlimab for treating haemolytic anaemia in people with cold agglutinin disease [ID6673] | Technology appraisal guidance |
| Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460] | Technology appraisal guidance |
| Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625] | Technology appraisal guidance |
| Talquetamab with pomalidomide or teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6629] | Technology appraisal guidance |
| Tarlatamab for maintenance treatment of extensive-stage small-cell lung cancer [ID6749] | Technology appraisal guidance |
| Tarlatamab for treating limited-stage small-cell lung cancer after chemoradiotherapy [ID6748] | Technology appraisal guidance |
| Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191] | Technology appraisal guidance |
| Technologies for the detection of Hepatocellular Carcinoma | HealthTech guidance |
| Technologies to improve detection of endometrial cancer | HealthTech guidance |
| Technology for cancer case finding using primary care records | HealthTech guidance |
| Teclistamab for treating relapsed or refractory multiple myeloma after 1 or more treatments including an anti-CD38 antibody and lenalidomide [ID6628] | Technology appraisal guidance |
| Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201] | Technology appraisal guidance |
| Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915] | Technology appraisal guidance |
| Tildrakizumab for treating active psoriatic arthritis [TSID12218] | Technology appraisal guidance |
| Timrepigene emparvovec for treating choroideremia [ID3916] | Technology appraisal guidance |
| Tiragolumab–atezolizumab for PD-L1-positive recurrent or advanced non-small-cell lung cancer untreated with checkpoint inhibitors [TSID12064] | Technology appraisal guidance |
| Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217] | Technology appraisal guidance |
| Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707] | Technology appraisal guidance |
| Tirzepatide for reducing the risk of major adverse cardiovascular events in people with type 2 diabetes and cardiovascular disease [ID6733] | Technology appraisal guidance |
| Tirzepatide for treating type 2 diabetes in people 10 to 17 years
[ID6539] | Technology appraisal guidance |
| Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683] | Technology appraisal guidance |
| Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6708] | Technology appraisal guidance |
| Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077] | Technology appraisal guidance |
| Tislelizumab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer [ID6304] | Technology appraisal guidance |
| Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158] | Technology appraisal guidance |
| Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682] | Technology appraisal guidance |
| Tocilizumab for treating systemic sclerosis [ID1396] | Technology appraisal guidance |
| Topical tapinarof for treating atopic dermatitis in people 2 years and over [ID6713] | Technology appraisal guidance |
| Topical tapinarof for treating mild to severe plaque psoriasis [ID6712] | Technology appraisal guidance |
| Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711] | Technology appraisal guidance |
| Transvaginal Ultrasound-Guided Radiofrequency Ablation (RFA) for Uterine Fibroids | HealthTech guidance |
| Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy [ID6509] | Technology appraisal guidance |
| Trastuzumab deruxtecan for neoadjuvant treatment of HER2-positive early breast cancer [ID6620] | Technology appraisal guidance |
| Trastuzumab deruxtecan for previously treated unresectable or advanced HER2-positive solid tumours [ID6511] | Technology appraisal guidance |
| Trastuzumab deruxtecan for untreated HER2-mutated unresectable advanced non-small-cell lung cancer [ID6603] | Technology appraisal guidance |
| Trastuzumab deruxtecan with or without pertuzumab for untreated HER2-positive metastatic breast cancer [ID6548] | Technology appraisal guidance |
| Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540] | Technology appraisal guidance |
| Treprostinil diethanolamine for treating pulmonary arterial hypertension [TSID11772] | Technology appraisal guidance |
| Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891] | Technology appraisal guidance |
| Troriluzole for spinocerebellar ataxia [ID6456] | Technology appraisal guidance |
| Tucatinib with pertuzumab and trastuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402] | Technology appraisal guidance |
| Tucatinib with trastuzumab and oxaliplatin-based chemotherapy for untreated HER2-positive metastatic or unresectable colorectal cancer [ID6755] | Technology appraisal guidance |
| Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781] | Technology appraisal guidance |
| Upadacitinib for treating moderate to severe hidradenitis suppurativa in people 12 years and over [ID6666] | Technology appraisal guidance |
| V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674] | Technology appraisal guidance |
| Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806] | Technology appraisal guidance |
| Vamikibart for treating uveitic macular oedema [ID6671] | Technology appraisal guidance |
| Veligrotug for treating thyroid eye disease [ID6636] | Technology appraisal guidance |
| Venglustat for treating type 3 Gaucher disease in people aged 12 and over after at least 3 years of enzyme replacement therapy [ID6295] | Technology appraisal guidance |
| VER-01 for treating chronic low back pain [ID6638] | Technology appraisal guidance |
| Vilobelimab for treating COVID 19 [TSID11815] | Technology appraisal guidance |
| Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736] | Technology appraisal guidance |
| Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807] | Technology appraisal guidance |
| WP1048 for treating grass pollen allergy in people aged 18 to 60 [TSID10467] | Technology appraisal guidance |
| Xanomeline tartrate–trospium chloride for treating schizophrenia [ID6716] | Technology appraisal guidance |
| Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity [TSID11902] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies [TSID10765] | Technology appraisal guidance |
| Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable [TSID10477] | Technology appraisal guidance |
| Zanidatamab with chemotherapy with or without tislelizumab for untreated HER2-positive unresectable advanced gastro-oesophageal adenocarcinoma [ID6672] | Technology appraisal guidance |
| Zanubrutinib with rituximab for untreated mantle cell lymphoma when a stem cell transplant is unsuitable [ID6641] | Technology appraisal guidance |
| Zasocitinib for treating moderate to severe plaque psoriasis [ID6700] | Technology appraisal guidance |
| Zavegepant for treating acute migraine
[TSID11998] | Technology appraisal guidance |
| Zilurgisertib for preventing new heterotopic ossification lesions caused by fibrodysplasia ossificans progressiva in people 12 years and over [ID6637] | Technology appraisal guidance |
| Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624] | Technology appraisal guidance |
| Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [TSID12040] | Technology appraisal guidance |
| Zongertinib for treating HER2-mutated unresectable or metastatic non-small-cell lung cancer [ID6573] | Technology appraisal guidance |